ChemSpider 2D Image | Azeliragon | C32H38ClN3O2

Azeliragon

  • Molecular FormulaC32H38ClN3O2
  • Average mass532.116 Da
  • Monoisotopic mass531.265259 Da
  • ChemSpider ID9355214

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

[3-(4-{2-BUTYL-1-[4-(4-CHLOROPHENOXY)PHENYL]-1H-IMIDAZOL-4-YL}PHENOXY)PROPYL]DIETHYLAMINE
1-Propanamine, 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl]phenoxy]-N,N-diethyl- [ACD/Index Name]
3-(4-{2-butil-1-[4-(4-clorofenoxi)fenil]-1H-imidazol- 4-il}fenoxi)-N,N-dietilpropan-1-amina [Spanish]
3-(4-{2-Butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl}phenoxy)-N,N-diethyl-1-propanamine [ACD/IUPAC Name]
3-(4-{2-Butyl-1-[4-(4-chlorophénoxy)phényl]-1H-imidazol-4-yl}phénoxy)-N,N-diéthyl-1-propanamine [French] [ACD/IUPAC Name]
3-(4-{2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl}phenoxy)-N,N-diethylpropan-1-amine
3-(4-{2-Butyl-1-[4-(4-chlorphenoxy)phenyl]-1H-imidazol-4-yl}phenoxy)-N,N-diethyl-1-propanamin [German] [ACD/IUPAC Name]
3-(4-{2-Butyl-1-[4-(4-chlorphenoxy)phenyl]-1H-imidazol-4-yl}phenoxy)-N,N-diethylpropan-1-amin
3-[4-[2-Butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl]phenoxy]-N,N-diethyl-1-propanamine
603148-36-3 [RN]
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

9945 [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Target Organs:

      Immunologic Factors TargetMol T2507

    • Bio Activity:

      Immunology/Inflammation TargetMol T2507
      Others MedChem Express HY-50682
      RAGE TargetMol T2507
      TTP488 is an antagonist at the Receptor for Advanced Glycation End products, is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD). MedChem Express
      TTP488 is an antagonist at the Receptor for Advanced Glycation End products, is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD).; Target: RAGE; in vitro: TTP488 is an orally active, centrally acting antagonist of RAGE-RAGE ligand interaction. MedChem Express HY-50682
      TTP488 is an antagonist at the Receptor for Advanced Glycation End products, is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD).;Target: RAGE;In vitro: TTP488 is an orally active, centrally acting antagonist of RAGE-RAGE ligand interaction. Chronic oral dosing of TTP488 in AD transgenic mice led to a reduction of amyloid load in the brain, improves performance on behavioral testing and normalization of electrophysiological recordings from hippocampal slices.[1];In vivo: The small molecule RAGE antagonist, TTP488, is developed by Trans-Tech Pharma. The TTP488 or control peptide is administered i.p. daily at a dose of 100 mcg/d.[3] Successful use of the RAGE inhibitor TTP488 in Phase II testing has led to a Phase III clinical trial for AD patients.[2] MedChem Express HY-50682

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

Density: 1.1±0.1 g/cm3
Boiling Point: 667.7±65.0 °C at 760 mmHg
Vapour Pressure: 0.0±2.0 mmHg at 25°C
Enthalpy of Vaporization: 98.2±3.0 kJ/mol
Flash Point: 357.6±34.3 °C
Index of Refraction: 1.572
Molar Refractivity: 157.6±0.5 cm3
#H bond acceptors: 5
#H bond donors: 0
#Freely Rotating Bonds: 14
#Rule of 5 Violations: 2
ACD/LogP: 8.98
ACD/LogD (pH 5.5): 3.85
ACD/BCF (pH 5.5): 62.84
ACD/KOC (pH 5.5): 58.19
ACD/LogD (pH 7.4): 4.96
ACD/BCF (pH 7.4): 815.82
ACD/KOC (pH 7.4): 755.50
Polar Surface Area: 40 Å2
Polarizability: 62.5±0.5 10-24cm3
Surface Tension: 39.8±7.0 dyne/cm
Molar Volume: 478.9±7.0 cm3

Click to predict properties on the Chemicalize site


Advertisement